Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find Radio Compass News for ALUNBRIG

    Client Email Product

    ALUNBRIG

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    INTERMEDIATES

    DOSSIERs // Finished Dosage Formulations

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    DIGITAL CONTENT

    PharmaCompass
    Product SearchProduct Search
    API SUPPLIERS
    API Suppliers

    API Suppliers

    8
    US DMFs Filed

    US DMFs Filed

    0

    CEP/COS Certifications

    CEP/COS Certifications

    0

    JDMFs Filed

    JDMFs Filed

    0

    Other Certificates

    Other Certificates

    0

    Other Suppliers

    Other Suppliers

    8
    API REF. PRICE (USD / KG)

    0

    API Market Place

    1
    INTERMEDIATES
    10
    DOSSIERS // FDF
    USA (Orange Book)

    USA (Orange Book)

    3
    Europe

    Europe

    0

    Canada

    Canada

    5
    Australia

    Australia

    4
    South Africa

    South Africa

    5
    Uploaded Dossiers

    Uploaded Dossiers

    0

    GLOBAL SALES (USD Million)

    U.S. Medicaid

    61.00

    Annual Reports

    0

    FDF Market Place

    1
    EXCIPIENTS
    92
    PATENTS & EXCLUSIVITIES

    USFDA Orange Book Patents

    12

    USFDA Exclusivities

    6
    DIGITAL CONTENT

    Blog #PharmaFlow

    1

    News

    34
    REF STANDARD

    EDQM

    0

    USP

    0

    JP

    0

    Other Listed Suppliers

    0

    SERVICES

    0

    left grey arrow
    right gray arrow
    • TABLET;ORAL - 180MG
    • TABLET;ORAL - 30MG
    • TABLET;ORAL - 90MG
    Full View ScreenFull Screen View
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint

    http://www.takedaoncology.com/media/news-media/news-releases/Takeda-Announces-Phase-3-Trial-of-ALUNBRIG-brigatinib-Met-Pr-10146/Print

    TAKEDAONCOLOGY
    22 Jan 2021
    Share Share
    Alunbrig scores NICE backing for ALK-positive lung cancer
    Alunbrig scores NICE backing for ALK-positive lung cancer

    http://www.pharmatimes.com/news/alunbrig_scores_nice_backing_for_alk_lung_cancer_1359892

    Lucy Parsons PHARMATIMES
    11 Dec 2020
    Share Share
    NICE authorises Takeda's Alunbrig for ALK-positive advanced NSCLC
    NICE authorises Takeda's Alunbrig for ALK-positive advanced NSCLC

    http://www.pharmafile.com/news/566013/nice-authorises-takedas-alunbrig-alk-positive-advanced-non-small-cell-lung-cancer

    PHARMAFILE
    10 Dec 2020
    Share Share
    ALUNBRIG?(brigatinib) now available on the NHS in England
    ALUNBRIG?(brigatinib) now available on the NHS in England

    https://www.pharmiweb.com/press-release/2020-12-10/alunbrig-brigatinib-now-available-on-the-nhs-in-england-wales-and-northern-ireland-for-adults-with-alk-positive-advanced-non-small-cell-lung-cancer

    PHARMIWEB
    10 Dec 2020
    Share Share
    Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO
    Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO

    https://www.businesswire.com/news/home/20200921005274/es

    BUSINESSWIRE
    21 Sep 2020
    Share Share
    New US approval for Takeda’s Alunbrig
    New US approval for Takeda’s Alunbrig

    http://www.pharmatimes.com/news/new_us_approval_for_takedas_alunbrig_1340874

    Selina McKee PHARMA TIMES
    25 May 2020
    Share Share
    U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
    U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment

    https://www.businesswire.com/news/home/20200522005448/en/U.S.-FDA-Approves-Takeda%E2%80%99s-ALUNBRIG%C2%AE-brigatinib-First-Line

    BUSINESSWIRE
    22 May 2020
    Share Share
    U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment
    U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment

    https://www.businesswire.com/news/home/20200522005448/en

    BUSINESSWIRE
    22 May 2020
    Share Share
    Expanded EU approval for Takeda's Alunbrig
    Expanded EU approval for Takeda's Alunbrig

    http://www.pharmatimes.com/news/expanded_eu_approval_for_takedas_alunbrig_1337936

    Selina McKee PHARMATIMES
    08 Apr 2020
    Share Share
    Takeda’s Alunbrig receives European marketing approval for ALK+ NSCLC
    Takeda’s Alunbrig receives European marketing approval for ALK+ NSCLC

    http://www.pharmabiz.com/NewsDetails.aspx?aid=122298&sid=2

    PHARMABIZ
    07 Apr 2020
    Share Share
    CHMP Recommends One New Drug, Begins Review of Indian CRO
    CHMP Recommends One New Drug, Begins Review of Indian CRO

    https://www.raps.org/news-and-articles/news-articles/2020/2/chmp-recommends-one-new-drug-begins-review-of-ind

    Michael Mezher RAPS
    29 Feb 2020
    Share Share
    Takeda Announces U.S. FDA Grants Priority Review for sNDA for ALUNBRIG®
    Takeda Announces U.S. FDA Grants Priority Review for sNDA for ALUNBRIG®

    https://www.businesswire.com/news/home/20200224005128/en/Takeda-Announces-U.S.-FDA-Grants-Priority-Review/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==

    BUSINESSWIRE
    24 Feb 2020
    Share Share
    Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib
    Takeda says cancer drug Alunbrig shows longer benefit vs. crizotinib

    https://www.reuters.com/article/us-takeda-pharma-alunbrig/takeda-says-cancer-drug-alunbrig-shows-longer-benefit-vs-crizotinib-idUSKBN1XX02D

    Rocky Swift REUTERS
    25 Nov 2019
    Share Share
    Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce of Xalkori
    Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce of Xalkori

    https://www.fiercepharma.com/marketing/takeda-eyes-alunbrig-earlier-lung-cancer-use-as-2-year-data-trounce-pfizer-s-xalkori

    Angus Liu FIERCE PHARMA
    23 Nov 2019
    Share Share
    Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products
    Takeda to Showcase Growing Pipeline & Diversified Portfolio of Oncology Products

    https://www.businesswire.com/news/home/20190516005860/en

    BUSINESSWIRE
    16 May 2019
    Share Share
    EU approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer
    EU approval for Takeda's Alunbrig in ALK+ advanced non-small cell lung cancer

    http://www.pharmafile.com/news/519468/european-approval-takedas-alunbrig-alk-advanced-non-small-cell-lung-cancer

    Matt Fellows PHARMA FILE
    29 Nov 2018
    Share Share
    Takeda Pharma's Alunbrig (brigatinib) Receives Approval in Europe
    Takeda Pharma's Alunbrig (brigatinib) Receives Approval in Europe

    https://www.ema.europa.eu/documents/product-information/alunbrig-epar-product-information_en.pdf

    EMA
    27 Nov 2018
    Share Share
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?
    Pfizer racks up 3rd cancer drug OK, but can it replace regular price hikes?

    https://endpts.com/pfizer-racks-up-its-third-cancer-drug-ok-in-2-months-but-is-it-enough-to-replace-regular-price-hikes/

    John Carroll ENDPTS
    02 Nov 2018
    Share Share
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC
    U.S. FDA Approves LORBRENA® (lorlatinib) for met NSCLC

    https://www.businesswire.com/news/home/20181102005583/en

    BUSINESSWIRE
    02 Nov 2018
    Share Share
    Takeda to Present Results on Efficacy of ALUNBRIG® (brigatinib) vs Crizotinib
    Takeda to Present Results on Efficacy of ALUNBRIG® (brigatinib) vs Crizotinib

    https://www.businesswire.com/news/home/20181019005217/en/Takeda-Present-Results-Phase-3-ALTA-1L-Trial

    BUSINESSWIRE
    19 Oct 2018
    Share Share
    Preliminary NICE ‘no’ for Takeda’s Alunbrig
    Preliminary NICE ‘no’ for Takeda’s Alunbrig

    http://www.pharmatimes.com/news/preliminary_nice_no_for_takedas_alunbrig_1254340

    Selina McKee PHARMA TIMES
    03 Oct 2018
    Share Share
    F-Prime, Atlas lead cancer startup Akrevia to $30M A round
    F-Prime, Atlas lead cancer startup Akrevia to $30M A round

    https://www.fiercebiotech.com/biotech/f-prime-atlas-lead-cancer-startup-akrevia-to-30m-a-round

    Nick Paul Taylor FIERCE BIOTECH
    27 Sep 2018
    Share Share
    Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial
    Takeda to Present Positive Data from ALUNBRIG® (brigatinib) ALTA-1L Trial

    https://www.businesswire.com/news/home/20180926005355/pt

    BUSINESSWIRE
    26 Sep 2018
    Share Share
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use
    Takeda's Alunbrig trounces Pfizer drug in bid for earlier ALK lung cancer use

    https://www.fiercepharma.com/marketing/takeda-alk-drug-alunbrig-trounces-pfizer-s-xalkori-bid-for-earlier-use

    Carly Helfand FIERCE PHARMA
    26 Sep 2018
    Share Share
    Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib)
    Takeda Receives Positive CHMP Opinion Recommending ALUNBRIG® (brigatinib)

    https://www.businesswire.com/news/home/20180921005287/en

    BUSINESSWIRE
    22 Sep 2018
    Share Share
    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018
    Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 September 2018

    https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-september-2018

    EMA
    22 Sep 2018
    Share Share
    CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys
    CHMP Backs 13 New Medicines, Maintains Negative Opinion of Sarepta’s Exondys

    https://www.raps.org/news-and-articles/news-articles/2018/9/chmp-backs-13-new-medicines-maintains-negative-op?utm_source=MagnetMail&utm_medium=Email%20&utm_campaign=RF%20Today%20%7C%2021%20September

    Michael Mezher RAPS
    21 Sep 2018
    Share Share
    Takeda lung cancer drug gets European panel nod
    Takeda lung cancer drug gets European panel nod

    https://health.economictimes.indiatimes.com/news/pharma/takeda-lung-cancer-drug-gets-european-panel-nod/65901196

    ECONOMIC TIMES
    21 Sep 2018
    Share Share
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint

    https://www.businesswire.com/news/home/20180725005065/en/Takeda-Announces-Phase-3-Trial-ALUNBRIG%C2%AE-brigatinib

    BUSINESSWIRE
    31 Jul 2018
    Share Share
    Takeda Announces Phase III Trial of ALUNBRIG For Lung Cancer
    Takeda Announces Phase III Trial of ALUNBRIG For Lung Cancer

    https://www.biospectrumasia.com/news/39/11380/takeda-announces-phase-iii-trial-of-alunbrig-for-lung-cancer.html

    BIOSPECTRUM
    26 Jul 2018
    Share Share
    Takeda R&D team rings the blockbuster bell with key PhIII success in frontline lung cancer
    Takeda R&D team rings the blockbuster bell with key PhIII success in frontline lung cancer

    https://endpts.com/takeda-rd-team-rings-the-blockbuster-bell-with-key-phiii-success-in-frontline-lung-cancer/

    John Carroll ENDPTS
    26 Jul 2018
    Share Share
    ASCO Soundbites, 2018 edition: Comments candid
    ASCO Soundbites, 2018 edition: Comments candid

    https://www.fiercepharma.com/pharma/asco-soundbites-vol-2-our-favorite-weekend-convo-snippets-from-execs-around-industry

    Carly Helfand FIERCE PHARMA
    04 Jun 2018
    Share Share
    Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at ASCO
    Takeda to Highlight Broad Oncology Portfolio and Pipeline Data at ASCO

    https://www.businesswire.com/news/home/20180517006004/en/Takeda-Highlight-Broad-Oncology-Portfolio-Pipeline-Data

    BUSINESSWIRE
    19 May 2018
    Share Share
    Pfizer files third-gen ALK inhibitor for lung cancer
    Pfizer files third-gen ALK inhibitor for lung cancer

    http://www.pmlive.com/pharma_news/pfizer_files_third-gen_alk_inhibitor_for_lung_cancer_1221723

    Phil Taylor PMLIVE
    14 Feb 2018
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    veranova-m-2024-04-22

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Access Virtual Booth

    Contact Supplier

    View Presentation

    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search